NYU LANGONE HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1841-01-01

Employees: 10K

Market Cap: -

Website: http://www.nyulangone.org

Clinical Trials

Training in the 21st Century: Using Virtual Role-Plays to Improve Nurse Communication for Medication Adherence

Not Applicable

Completed

Conditions: Hypertension
High Blood Pressure

Interventions: Behavioral: Audiotaped Counseling Session

First Posted Date: 2018-07-26

Last Posted Date: 2022-02-14

Lead Sponsor: NYU Langone Health

Target Recruit Count: 26

Registration Number: NCT03599050

Locations: 🇺🇸
NYU School of Medicine, New York, New York, United States

Use of Disposable Stethoscope Covers for Reduction of Stethoscope MRSA Contamination

Not Applicable

Completed

Conditions: MRSA

Interventions: Other: Daily Antimicrobial Stethoscope Diaphragm Cover
Other: Uncovered Stethoscopes

First Posted Date: 2018-07-26

Last Posted Date: 2019-09-13

Lead Sponsor: NYU Langone Health

Target Recruit Count: 1

Registration Number: NCT03601741

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

P20 Extending Sleep to Reverse Metabolic Syndrome

Not Applicable

Completed

Conditions: Metabolic Syndrome

Interventions: Behavioral: Sleep Intervention
Behavioral: Week 2 Intervention

First Posted Date: 2018-07-24

Last Posted Date: 2024-11-19

Lead Sponsor: NYU Langone Health

Target Recruit Count: 44

Registration Number: NCT03596983

Locations: 🇺🇸
New York University, New York, New York, United States

Association Between Inpatient Steps Per Day and Patient Functional Status/Disposition

Not Applicable

Completed

Conditions: Physical Medicine

Interventions: Other: Standard of Care
Behavioral: Ambulation

First Posted Date: 2018-07-23

Last Posted Date: 2020-05-29

Lead Sponsor: NYU Langone Health

Target Recruit Count: 51

Registration Number: NCT03595605

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

A Futility Trial of Sirolimus in Multiple System Atrophy

Phase 2

Terminated

Conditions: Multiple System Atrophy

Interventions: Other: Placebo
Drug: Sirolimus 2 MG

First Posted Date: 2018-07-18

Last Posted Date: 2021-12-07

Lead Sponsor: NYU Langone Health

Target Recruit Count: 47

Registration Number: NCT03589976

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Food Intake REstriction for Health OUtcome Support and Education (FIREHOUSE) Trial

Completed

Conditions: Lung Injury
Particulate Matter Inhalation Injury

Interventions: Dietary Supplement: Low-Calorie Mediterranean Diet
Other: Usual care group
Combination Product: Technology based monitoring and behavioral participation

First Posted Date: 2018-07-10

Last Posted Date: 2021-12-03

Lead Sponsor: NYU Langone Health

Target Recruit Count: 100

Registration Number: NCT03581006

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: Trametinib daily Until PD
Drug: CDX-3379 (ERBB3 antibody)

First Posted Date: 2018-07-09

Last Posted Date: 2020-05-20

Lead Sponsor: NYU Langone Health

Target Recruit Count: 3

Registration Number: NCT03580382

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Radiographic and Clinical Comparison of Post-reduction Splinting Constructs in the Treatment of Acute Displaced Distal Radius Fractures

Not Applicable

Completed

Conditions: Radius Fractures

Interventions: Other: Sugar Tong Splint
Other: Clam Shell Splint

First Posted Date: 2018-06-27

Last Posted Date: 2021-09-05

Lead Sponsor: NYU Langone Health

Target Recruit Count: 87

Registration Number: NCT03570905

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: Mocetinostat Induction Phase + Ipilimumab + Nivolumab
Drug: Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab

First Posted Date: 2018-06-21

Last Posted Date: 2020-05-21

Lead Sponsor: NYU Langone Health

Target Recruit Count: 11

Registration Number: NCT03565406

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Assessment of tDCS-Induced Neuronal Responses in Multiple Sclerosis (MS) With Advanced MRI

Not Applicable

Completed

Conditions: Multiple Sclerosis

Interventions: Device: tDCS Administration during MRI
Device: Remotely-supervised Daily tDCS Administration
Device: Optional 15 minutes of imaging + simultaneous tDCS up to 4.0mA

First Posted Date: 2018-06-20

Last Posted Date: 2024-01-17

Lead Sponsor: NYU Langone Health

Target Recruit Count: 73

Registration Number: NCT03564496

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy